The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: A cluster randomized controlled trial, targeting the care of individuals with diabetes and hypertension in Ontario, Canada

Implementation Science

Volumn 2, Issue 1, 2007, Pages

  Zwarenstein, Merrick ^a,b,c,f,g   Hux, Janet E ^a,b,c   Kelsall, Diane ^a,c   Paterson, Michael ^a   Grimshaw, Jeremy ^d,e,h   Davis, Dave ^c   Laupacis, Andreas ^a,b,c   Evans, Michael ^f   Austin, Peter C ^a,g   Slaughter, Pamela M ^a   Shiller, Susan K ^a   Croxford, Ruth ^a   Tu, Karen ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h Canada Research Department in Health Knowledge Transfer and Uptake   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38749091222     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-2-37     Document Type: Article

References (60)

1. Evidence based general practice: a retrospective study of interventions in one training practice. P Gill AC Dowell RD Neal N Smith P Heywood AE Wilson, BMJ 1996 312 819 821 8608291
2. Guidelines in general practice: the new Tower of Babel? A Hibble D Kanka D Pencheon F Pooles, BMJ 1998 317 862 863 9748185
3. Changing provider behavior: an overview of systematic reviews of interventions. JM Grimshaw L Shirran R Thomas G Mowatt C Fraser L Bero R Grilli E Harvey A Oxman MA O'Brien, Med Care 2001 39 II2 45 10.1097/00005650-200108002- 00002 11583120
4. I Medicine, Guidelines for clinical practice: From development to use Washington, DC, National Academy Press, MJ F and KN L, 1992
5. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. AD Oxman MA Thomson DA Davis RB Haynes, Can Med Assoc J 1995 153 1423 1431
6. Printed Educational Materials: effects on professional practice and health care outcomes. (Cochrane Review). N Freemantle EL Harvey G JM R Grilli LA Bero, The Cochrane Library Oxford, Update Software 2000
7. Effectiveness and efficiency of guideline dissemination and implementation strategies. JM Grimshaw RE Thomas G MacLennan C Fraser CR Ramsay L Vale P Whitty MP Eccles L Matowe L Shirran M Wensing R Dijkstra C Donaldson, Health Technol Assess 2004 8 iii 72 14960256
8. Personal paper. Beliefs and evidence in changing clinical practice. R Grol, BMJ 1997 315 418 421 9277610
9. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. G Worrall P Chaulk D Freake, Can Med Assoc J 1997 156 1705 1712
10. Epidemiology of arthritis and osteoporosis. H G, Patterns of Health Care in Ontario: Arthritis and Related Conditions Toronto, Institute for Clinical Evaluative Sciences, JI W and Badley EM, 1998 1 10
11. Incidence and prevalence of diabetes in Manitoba, 1986-1991. JF Blanchard S Ludwig A Wajda H Dean K Anderson O Kendall N Depew, Diabetes Care 1996 19 807 811 10.2337/diacare.19.8.807 8842595
12. Epidemiology of diabetes mellitus in Canada. MH Tan DR MacLean, Clin Invest Med 1995 18 240 246 8549008
13. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. JE Hux F Ivis V Flintoft A Bica, Diabetes Care 2002 25 512 516 10.2337/diacare.25.3.512 11874939
14. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. AI Adler IM Stratton HA Neil JS Yudkin DR Matthews CA Cull AD Wright RC Turner RR Holman, BMJ 2000 321 412 419 10938049 10.1136/bmj.321.7258.412
15. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. L Hansson A Zanchetti SG Carruthers B Dahlof D Elmfeldt S Julius J Menard KH Rahn H Wedel S Westerling, Lancet 1998 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947
16. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998 317 703 713 9732337
17. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000 355 253 259 10.1016/S0140-6736(99)12323-7 10675071
18. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. RO Estacio BW Jeffers WR Hiatt SL Biggerstaff N Gifford RW Schrier, N Engl J Med 1998 338 645 652 10.1056/NEJM199803053381003 9486993
19. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. P Tatti M Pahor RP Byington P Di Mauro R Guarisco G Strollo F Strollo, Diabetes Care 1998 21 597 603 10.2337/diacare.21.4.597 9571349
20. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998 317 713 720 9732338
21. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001 134 370 379 11242497
22. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. J Shepherd SM Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard, N Engl J Med 1995 333 1301 1307 10.1056/NEJM199511163332001 7566020
23. Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators. MA Pfeffer FM Sacks LA Moye L Brown JL Rouleau LH Hartley J Rouleau R Grimm F Sestier W Wickemeyer, Am J Cardiol 1995 76 98C 106C 10.1016/S0002-9149(99)80478-0 7572695
24. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 339 1349 1357 10.1056/NEJM199811053391902 9841303
25. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). K Pyorala TR Pedersen J Kjekshus O Faergeman AG Olsson G Thorgeirsson, Diabetes Care 1997 20 614 620 10.2337/diacare.20.4.614 9096989
26. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere A Langendorfer EA Stein W Kruyer AM Gotto Jr., JAMA 1998 279 1615 1622 10.1001/jama.279.20.1615 9613910
27. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. JG Fodor JJ Frohlich JJ Genest Jr. PR McPherson, Can Med Assoc J 2000 162 1441 1447
28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001 285 2486 2497 10.1001/jama.285.19.2486 11368702
29. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. SM Haffner S Lehto T Ronnemaa K Pyorala M Laakso, N Engl J Med 1998 339 229 234 10.1056/NEJM199807233390404 9673301
30. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. L Mykkanen J Kuusisto K Pyorala M Laakso, Diabetologia 1993 36 553 559 10.1007/BF02743273 8335178
31. Risk factor clustering in patients with hypertension and non-insulin-dependent diabetes mellitus. The Skaraborg Hypertension Project. E Bog-Hansen U Lindblad K Bengtsson J Ranstam A Melander L Rastam, J Intern Med 1998 243 223 232 10.1046/j.1365-2796.1998.0327h.x 9627160
32. Hypertension and related risk factors in type 2 diabetes mellitus. M Lunetta A Barbagallo S Crimi M Di Mauro L Sangiorgio L Mughini, Panminerva Med 1998 40 169 173 9785910
33. Prevalence of hypertension in patients with type II diabetes in referral versus primary care clinics. WV Moore D Fredrickson A Brenner B Childs O Tatpati JM Hoffman R Guthrie, J Diabetes Complications 1998 12 302 306 10.1016/S1056-8727(98)00009-9 9877462
34. Diabetic eye disease. R Klein BE Klein, Lancet 1997 350 197 204 10.1016/S0140-6736(97)04195-0 9250197
35. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991 98 766 785 2062512
36. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985 103 1796 1806 2866759
37. How effective are treatments for diabetic retinopathy? FL Ferris III, JAMA 1993 269 1290 1291 10.1001/jama.269.10.1290 8437309
38. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. S Meltzer L Leiter D Daneman HC Gerstein D Lau S Ludwig JF Yale B Zinman D Lillie, Can Med Assoc J 1998 159 Suppl 8:S1-29. S1 29
39. Diabetic Retinopathy - Preferred Practice Pattern. W CP B MA C EY, American Ophthalmology Society 1998
40. H J, Diabetes in Ontario: An ICES Practice Atlas Toronto, Institute for Clinical Evaluative Sciences 2003 (in press)
41. Report of the Canadian Hypertension Society's consensus conference on the management of mild hypertension. AG Logan, Can Med Assoc J 1984 131 1053 1057 6149806
42. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. FH Messerli E Grossman U Goldbourt, JAMA 1998 279 1903 1907 10.1001/jama.279.23.1903 9634263
43. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. JA Staessen R Fagard L Thijs H Celis GG Arabidze WH Birkenhager CJ Bulpitt PW de Leeuw CT Dollery AE Fletcher F Forette G Leonetti C Nachev ET O'Brien J Rosenfeld JL Rodicio J Tuomilehto A Zanchetti, Lancet 1997 350 757 764 10.1016/S0140-6736(97)05381-6 9297994
44. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. L Hansson LH Lindholm T Ekbom B Dahlof J Lanke B Schersten PO Wester T Hedner U de Faire, Lancet 1999 354 1751 1756 10.1016/S0140-6736(99)10327-1 10577635
45. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. B Neal S MacMahon N Chapman, Lancet 2000 356 1955 1964 10.1016/S0140-6736(00) 03307-9 11130523
46. The 2000 Canadian recommendations for the management of hypertension: Part one - therapy. FA McAlister M Levine KB Zarnke N Campbell R Lewanczuk F Leenen S Rabkin JM Wright J Stone RD Feldman M Lebel G Honos G Fodor E Burgess S Tobe P Hamet R Herman J Irvine B Culleton R Petrella R Touyz, Can J Cardiol 2001 17 543 559 11381277
47. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 288 2998 3007 10.1001/jama.288.23.2998 12479764
48. Hypertension guidelines in elderly patients: is anybody listening? K Tu MM Mamdani JV Tu, Am J Med 2002 113 52 58 10.1016/S0002-9343(02)01144-0 12116987
49. Prevalence and Treatment of Hypertension Complicated by Comorbid Conditions. JL Meier J Lopez D Siegel, J Clin Hypertens 1999 1 209 211
50. Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow-up of hypertension. K Tu D Davis, J Contin Educ Health Prof 2002 22 11 22 10.1002/chp.1340220103 12004636
51. Designing a quality improvement intervention: a systematic approach. B MA K G W T, Qual Saf Health Care 2003
52. A Donner K N, Design and Analysis of Cluster Ramdomization Trials in Health Research London, Arnold 2003
53. M DM, Design and Analysis of Group-Randomized Trials New York, Oxford University Press 1998 1 467
54. The Theory of Planned Behaviour. A I, Organizational Behaviour and Human Decision Processes 1991 50 179 211 10.1016/0749-5978(91)90020-T
55. An introduction to multilevel regression models. PC Austin V Goel C van Walraven, Can J Public Health 2001 92 150 154 11338155
56. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. GM Anderson MH Beers K Kerluke, J Eval Clin Pract 1997 3 283 294 10.1046/j.1365-2753.1997.t01-1-00005.x 9456428
57. Relation between physician characteristics and prescribing for elderly people in New Brunswick. W Davidson DW Molloy G Somers M Bedard, Can Med Assoc J 1994 150 917 921
58. Econometric Models and Economic Forecasts. P RS R DL, New York, Irwin McGraw-Hill 4th 1998 15
59. Distribution of the estimators for autoregressive time series with a unit root. D DA F WA, J Am Stat Assoc 1979 74 427 431 10.2307/2286348
60. On a measure of lack of fit in time series models. L GM B GEP, Biometrika 1978 65 297 303 10.1093/biomet/65.2.297